91³ÉÈ˵¼º½

This two-year Hematology-Oncology Clinical Development fellowship provides extensive exposure to clinical development activities and fosters an understanding of clinical research principles. The fellow will function as a Clinical Scientist and will support Medical Directors/senior-level Clinical Scientists on a diverse set of clinical development activities.

BeiGene has built an extensive array of novel in vitro, ex vivo and in vivo cancer models to help better select targets, and to screen and evaluate agents that may have significant potential (alone or in combination). By integrating elements of the human immune system, their cancer models enable them to evaluate potential drug candidates in conditions that mimic cancer at the time of treatment. This is especially significant when drug discovery depends on evaluating multiple combinations and regimens that target specific mutations while simultaneously immobilizing cancer cells’ defenses. In the role of a Clinical Scientist, the fellow will gain a strong foundation in clinical oncology research.

Activities at BeiGene:

The fellow will function as a clinical scientist and will support medical directors/senior level clinical scientists on the following activities:

• Serve as a clinical science representative on cross-functional sub-teams (i.e. protocol execution, clinical, biomarkers, pharmacokinetics)
• Create, review and present clinical slides for internal (i.e. BeiGene) and external meetings (e.g. Investigator meetings, scientific congresses, advisory boards, site visits, site staff training)
• Develop understanding of Good Clinical Practice (GCP), International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), FDA, EMA, NICE and other relevant guidelines and regulations
• Draft abstracts, posters, manuscripts for scientific meetings
• Author and review of clinical documents (i.e. clinical trial protocols, clarifications and amendments, informed consents, investigator brochures, clinical study reports, investigational new drug submissions)
• Respond to inquiries from health authorities (e.g. FDA, EMA) and study site ethics committees
• Partner with the data management team to assist with the development of case report forms
• Serve as a primary point of contact for study inquiries
• Contribute to ongoing review of the integrity of clinical trial data
• Develop understanding of the entire clinical development process from Phase I-IV

Fellowship Program Dates

The fellowship begins July 1, 2025 and ends June 30, 2027.